ARCHIVES

NIDA Supports Phase III Trial of Anti-Tobacco Vaccine

This article is from The Cancer Letter archive.

Vol. 35 No. 41 | November 6, 2009

Download PDF Visit The Full Archive

Related Articles

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

December 30, 2011

Young Takes Over Centers & Community Oncology, Says Biggest Problem Is Getting Adequate Funds

April 8, 1988

Prevention Facility For Intramural Research Approved, Also Would Involve Academic Investigators

November 1, 1991

FDA Approves Avastin For Recurrent NSCLC

October 27, 2006

Group Chairmen Criticize NCI Budget Priorities

July 11, 2003

USDA Expands Role In 5 A Day Partnership

April 26, 2002